CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 261 enrolled
Drug / intervention
Ranibizumab +1 moredrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00996437
NCT00996437Phase 3Completed
CompareCT.gov

An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy

Jaeb Center for Health Research·interventional·Posted Oct 16, 2009·Updated Aug 26, 2016

In Brief

A Phase 3 clinical trial evaluating Ranibizumab and Saline for Vitreous Hemorrhage and Proliferative Diabetic Retinopathy. Completed, enrolled 261 participants across 67 sites.

Detailed Summary

This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eyes presenting with vitreous hemorrhage from proliferative diabetic retinopathy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitreous Hemorrhage, Proliferative Diabetic Retinopathy
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 16, 2009
Enrollment StartJun 1, 2010
Primary CompletionFeb 1, 2012
Study CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.7 years ago

Interventions

Ranibizumabdrug

Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks

Salinedrug

Saline injection of 0.5mg at baseline, 4 and 8 weeks